Navigation Links
Repros Reports That Proellex Has Demonstrated Superior Efficacy and,Safety in Endometriosis When Compared to Standard of Drug Care

THE WOODLANDS, Texas--(BUSINESS WIRE)--Jun 11, 2007 - Repros Therapeutics Inc. (NasdaqGM:RPRX) today released top-line findings from its six month study of Proellex in the treatment of endometriosis. This study, conducted in Europe, enrolled 39 premenopausal women and has completed six months of dosing. The study included three dose levels of Proellex(TM) as well as a positive control arm. The positive control was Lucrin(R), a GnRH agonist also known as Lupron(R) or leuprolide acetate, commonly used for the treatment of endometriosis. Proellex was administered in a double blinded fashion as a daily oral dose of either 12.5mg, 25mg, or 50mg capsules. Data from this study demonstrate that treatment with the 50mg Proellex dose reduces both the duration and intensity of pain more effectively than 12.5mg or 25mg and is significantly better (p = 0.0012) than Lucrin in reducing the number of days of pain over the course of the study. Pain reduction also occurred more rapidly than with the active control, Lucrin. Biomarkers of bone loss were unchanged on Proellex therapy but increased on Lucrin.

Pain Results

Pain is the most prevalent and debilitating symptom of endometriosis. The response of pain to treatment in this study was analyzed in 2 ways. Patients in the study maintained daily pain diaries to record the severity and frequency of pain. In addition, at each office visit, patients filled out endometriosis symptom surveys that included a questionnaire that evaluated intensity of pain on a bad day on a scale of 0-10, with 10 being the greatest intensity.

Over the 180 day treatment period, pain diaries indicated that women on the 50mg Proellex dose had 170 or 96% pain free days (standard deviation 8.86 days). This decrease in duration of pain was statistically significantly better (p = 0.0012) than the 117.8 (74%; standard deviation 51.4 days) pain free days achieved with Lucrin. The 50mg dose of Proel
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Peer Reviewed Journal Article Indicates Repros Proellex Exhibits Potential for New Approach to the Treatment and Prevention of Breast Cancer
2. Repros Androxal Shows Highly Statistically Significant Positive Effects in Men with Secondary Hypogonadism
3. Repros Proellex Shows Statistically Significant Improvement in Primary Endpoint in Phase 2 Trial in the Treatment of Uterine Fibroids
4. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
5. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
6. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
7. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
8. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
9. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
10. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
11. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
Post Your Comments:
(Date:10/30/2014)... 29, 2014   ViaDerma, Inc. (OTCQB: ... new products to market, is committed to pursuing ... developed an innovative, patent-pending dual carrier transdermal delivery ... pharmaceutical active ingredients to penetrate the skin and ... The transdermal delivery method also overcomes microbial drug ...
(Date:10/30/2014)... , Oct. 30, 2014 Today Eli ... details of its long-standing technology transfer program to increase ... Begun in 2003, the effort included Lilly donating manufacturing ... in China , India ... South Africa – all MDR-TB ,hot ...
(Date:10/27/2014)... CHICAGO , Oct. 27, 2014  Demonstrations ... and devices are being featured this week in ... 2014 Scientific Assembly where more than 7,000 emergency ... medicine and participating in educational courses. ... back drop of true-to-life emergency department environments, including ...
Breaking Medicine Technology:ViaDerma, Inc. Announces Plans to Pursue Out-Licensing Partnerships in 2015 2ViaDerma, Inc. Announces Plans to Pursue Out-Licensing Partnerships in 2015 3Lilly Shares Insights from Decade-Long Technology Transfer Experience 2Lilly Shares Insights from Decade-Long Technology Transfer Experience 3Lilly Shares Insights from Decade-Long Technology Transfer Experience 4Emergency Medicine of the Future Demonstrated at ACEP14 2Emergency Medicine of the Future Demonstrated at ACEP14 3Emergency Medicine of the Future Demonstrated at ACEP14 4Emergency Medicine of the Future Demonstrated at ACEP14 5Emergency Medicine of the Future Demonstrated at ACEP14 6Emergency Medicine of the Future Demonstrated at ACEP14 7Emergency Medicine of the Future Demonstrated at ACEP14 8Emergency Medicine of the Future Demonstrated at ACEP14 9Emergency Medicine of the Future Demonstrated at ACEP14 10Emergency Medicine of the Future Demonstrated at ACEP14 11Emergency Medicine of the Future Demonstrated at ACEP14 12Emergency Medicine of the Future Demonstrated at ACEP14 13Emergency Medicine of the Future Demonstrated at ACEP14 14Emergency Medicine of the Future Demonstrated at ACEP14 15
(Date:10/29/2014)... study has found that certain prostate cancer medications are ... causes in men with congestive heart failure or prior ... findings will help doctors and patients weigh the benefits ... therapy (ADT), which reduces levels of male hormones in ... is a mainstay of treatment for prostate cancer. Despite ...
(Date:10/28/2014)... 27, 2014)—Although oral hormonal therapy is known to ... hormone receptor–positive tumors, about one-half of patients fail ... by Columbia University Medical Center (CUMC) researchers has ... (the most common type of hormone therapy), which ... increased treatment adherence by 50 percent. , The ...
(Date:10/27/2014)... for informal caregiving of elderly people by friends and ... a year, according to a new RAND Corporation study. ... minimum wage would cost $221 billion, while replacing ... annually. , The study, published online by the ... the value of informal caregiving by making use of ...
(Date:10/27/2014)... adopt a new therapy by watching others use it, ... , New technology is like an influential colleague -- ... reminded every five to seven days , CHICAGO ... when they are persuaded to do so by an influential ... adopting innovations also have relevance for business, education and research. ...
(Date:10/27/2014)... (PRWEB) October 27, 2014 CALNOC, ... announced its annual CALNOC Performance Excellence Awards recognizing ... of reducing hospital acquired pressure ulcers, injuries from ... their commitment and dedication to nursing quality. , ... and affiliation. These hospitals have a long and ...
Breaking Medicine News(10 mins):Health News:Prostate cancer medications linked with increased risk of heart-related deaths in men with cardiovascular problems 2Health News:Generic medications boost adherence to breast cancer therapy 2Health News:Generic medications boost adherence to breast cancer therapy 3Health News:Cost of informal caregiving for US elderly is $522 billion annually, study finds 2Health News:Persuading doctors to quickly adopt new treatments 2Health News:Persuading doctors to quickly adopt new treatments 3Health News:CALNOC Presents Performance Excellence Awards to Hospitals at Annual Conference in San Diego 2Health News:CALNOC Presents Performance Excellence Awards to Hospitals at Annual Conference in San Diego 3Health News:CALNOC Presents Performance Excellence Awards to Hospitals at Annual Conference in San Diego 4
... Texas, Dec. 17 ULURU Inc. (Amex:,ULU) today ... Allowance from the,United States Patent and Trademark Office ... the underlying science behind the Company,s,nanoparticle aggregate technology; ... patent portfolio., Commenting on the issuance of ...
... 17 CSG/SportsCoatings,today announced a major deal ... and FabricAide(TM), to 25 high schools in,Virginia,s ... School District is the model for how ... steps towards minimizing prevalent,bacterial issues like staph ...
... acute and recurrent chronic pain are the leading causes of ... low as 2 percent when these soldiers are treated outside ... percent when troops and officers are treated and managed for ... for therapy, according to a new study from a Johns ...
... Researchers at Oregon Health & Science University have ... a study that suggests new strategies may be in ... The research is published in the current edition of ... The research focused on an important component of the ...
... cardiac safety, TAMPA, Fla., Dec. 17 ... in electro-stun technology, today,announced a major research university ... Systems, S-200 projectile stun gun. Details of the,study ... meeting and/or,in a scientific journal. However, this study ...
... Available Today, Offers Great ... and Now Even More Heart Benefits, HORSHAM, ... -- and then bulge -- from holiday parties ... availability of,NutriSystem Advanced, the company,s breakthrough weight-loss, health ...
Cached Medicine News:Health News:ULURU Inc. Announces Issuance of Notice of Allowance for Nanoparticle Aggregate Patent 2Health News:Virginia School District Gets Proactive Against MRSA 2Health News:Pain treatment in the field: Good for soldiers' comfort and better for rebuilding troop strength 2Health News:OHSU research suggests new strategy for protecting aging Americans against infectious disease 2Health News:Medical Study of Stinger S-200 Stun Gun Completed 2Health News:With Calorie Counting on Holiday Hiatus, NutriSystem Offers 'Advanced' Resolution for 2008 2Health News:With Calorie Counting on Holiday Hiatus, NutriSystem Offers 'Advanced' Resolution for 2008 3Health News:With Calorie Counting on Holiday Hiatus, NutriSystem Offers 'Advanced' Resolution for 2008 4
... powerful, lightweight, easy to ... durable foam silicone rubber ... by machine washable cotton ... easily adjusts to all ...
Xenon surgical headlight system is durable, comfortable, lightweight and deliver dependable bright light through a patented shielded fiber optic bundle. It is easy to wear....
View Mex-3 is designed for out-patient surgery, hospital rounds and house calls....
Headlight module is mounted on UltraLite Plus sweatband....
Medicine Products: